Literature DB >> 1607608

Inflammatory bowel disease: medical cost algorithms.

A R Hay1, J W Hay.   

Abstract

In this study we describe medical cost estimates for the two major types of inflammatory bowel disease, Crohn's disease and ulcerative colitis, using a literature-based medical decision algorithm costing methodology. Surgery and inpatient costs were estimated to account for roughly half of inflammatory bowel disease medical costs. Outpatient medical care represented only 3.0-7.1% of average cost of medical care for inflammatory bowel disease; initial diagnostic workups were only 1.5-7.8% of medical costs. Long-term complications were estimated to average $439 for ulcerative colitis, nearly twice the average for Crohn's disease. Medications averaged about 10% of total costs. The average annual medical cost per patient with Crohn's disease was estimated at $6,561 (1990 U.S. dollars). The total annual medical costs for U.S. Crohn's disease patients in 1990 was estimated at $1.0-1.2 billion. The average annual medical cost per patient with ulcerative colitis was estimated at $1,488. The total annual medical costs for U.S. patients with ulcerative colitis in 1990 was estimated at $0.4-0.6 billion.

Entities:  

Mesh:

Year:  1992        PMID: 1607608     DOI: 10.1097/00004836-199206000-00010

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

Review 1.  Infliximab treatment for Crohn's disease.

Authors:  C A Conroy; R Cattell
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

2.  A short term cost-effectiveness model for oral antidiabetic medicines in Europe.

Authors:  S C Hood; L Annemans; M Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

3.  Health care costs of complex perianal fistula in Crohn's disease.

Authors:  M Chaparro; C Zanotti; P Burgueño; I Vera; F Bermejo; I Marín-Jiménez; C Yela; P López; M D Martín; C Taxonera; B Botella; R Pajares; A Ponferrada; M Calvo; A Algaba; L Pérez; B Casis; J Maté; J Orofino; N Lara; M García-Losa; X Badia; J P Gisbert
Journal:  Dig Dis Sci       Date:  2013-09-13       Impact factor: 3.199

Review 4.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 5.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

Authors:  Andrew P Yu; Scott Johnson; Si-Tien Wang; Pavel Atanasov; Jackson Tang; Eric Wu; Jingdong Chao; Parvez M Mulani
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 8.  The pharmacoeconomics of biologic therapy for IBD.

Authors:  Russell D Cohen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

9.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

Review 10.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.